ProQR Therapeutics N.V. (PRQR) stock
PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.10−0.05 (-4.35%)
Close on Nov 18, 2026Market cap $115.90MP/E –Yield –
ProQR Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
ProQR Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -€42.85M. For fiscal 2025 it was -€43.45M. The highest annual figure on record is -€27.00M in fiscal 2015.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€43.45M | – |
| FY2024 | Dec 31, 2024 | -€30.47M | – |
| FY2023 | Dec 31, 2023 | -€31.86M | – |
| FY2022 | Dec 31, 2022 | -€65.16M | – |
| FY2021 | Dec 31, 2021 | -€57.21M | – |
| FY2020 | Dec 31, 2020 | -€42.37M | – |
| FY2019 | Dec 31, 2019 | -€57.45M | – |
| FY2018 | Dec 31, 2018 | -€36.29M | – |
| FY2017 | Dec 31, 2017 | -€40.50M | – |
| FY2016 | Dec 31, 2016 | -€39.57M | – |
| FY2015 | Dec 31, 2015 | -€27.00M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -€8.82M | – |
| Q1 FY2026 | Mar 31, 2026 | -€13.65M | – |
| Q4 FY2025 | Dec 31, 2025 | -€9.10M | – |
| Q3 FY2025 | Sep 30, 2025 | -€11.28M | – |
| Q2 FY2025 | Jun 30, 2025 | -€12.25M | – |
| Q1 FY2025 | Mar 31, 2025 | -€10.82M | – |
| Q4 FY2024 | Dec 31, 2024 | -€10.08M | – |
| Q3 FY2024 | Sep 30, 2024 | -€8.72M | – |
| Q2 FY2024 | Jun 30, 2024 | -€3.60M | – |
| Q1 FY2024 | Mar 31, 2024 | -€8.08M | – |
| Q4 FY2023 | Dec 31, 2023 | -€6.27M | – |
| Q3 FY2023 | Sep 30, 2023 | -€7.39M | – |
| Q2 FY2023 | Jun 30, 2023 | -€8.81M | – |
| Q1 FY2023 | Mar 31, 2023 | -€9.39M | – |
| Q4 FY2022 | Dec 31, 2022 | -€12.46M | – |
| Q3 FY2022 | Sep 30, 2022 | -€19.82M | – |
| Q2 FY2022 | Jun 30, 2022 | -€15.83M | – |
| Q1 FY2022 | Mar 31, 2022 | -€17.04M | – |
| Q4 FY2021 | Dec 31, 2021 | -€17.33M | – |
| Q3 FY2021 | Sep 30, 2021 | -€14.56M | – |
| Q2 FY2021 | Jun 30, 2021 | -€13.20M | – |
| Q1 FY2021 | Mar 31, 2021 | -€12.10M | – |
| Q4 FY2020 | Dec 31, 2020 | -€11.67M | – |
| Q3 FY2020 | Sep 30, 2020 | -€10.86M | – |
| Q2 FY2020 | Jun 30, 2020 | -€3.36M | – |
| Q1 FY2020 | Mar 31, 2020 | -€16.48M | – |
| Q4 FY2019 | Dec 31, 2019 | -€17.42M | – |
| Q3 FY2019 | Sep 30, 2019 | -€13.45M | – |
| Q2 FY2019 | Jun 30, 2019 | -€11.84M | – |
| Q1 FY2019 | Mar 31, 2019 | -€14.74M | – |
| Q4 FY2018 | Dec 31, 2018 | -€12.85M | – |
| Q3 FY2018 | Sep 30, 2018 | -€5.92M | – |
| Q2 FY2018 | Jun 30, 2018 | -€7.67M | – |
| Q2 FY2017 | Jun 30, 2017 | -€10.18M | – |
See a number that looks wrong?